Forgot your password?
New User?
Remember me
banner banner

You are here:Home » Antibodies » Antibodies-Protein C » Anti -Protein C

Anti -Protein C


  For pricing information, USA customers sign in.
  Outside USA? Please contact your distributor for pricing.


Clone Host Grade Applications
Polyclonal Goat Serum E IP
Protein C is a glycoprotein (MW 60000) which is synthesized in the liver. It acts as a trypsin like serine protease but functions in a manner different from that of antithrombin III. Activated protein C (pCa) results from proteolytic cleavage of protein C by thrombin and with protein S (pS) as a cofactor it cleaves factors Va and VIIIa, producing anti-coagulation by decreasing the conversion of prothrombin to thrombin. It also stimulates the fibrinolytic system by inactivating the inhibitor of tissue plasminogen activator (TPA), an enzyme that converts plasminogen into plasmin which cleaves fibrin into fibrin split products. Protein C is consumed during coagulation in vivo. Very little protein C is activated during coagulation in vitro, because this requires the presence of thrombomodulin, a thrombin receptor on endothelial cells. The coagulant activity of
protein C is species specific and pCa is specifically regulated by protein C inhibitor (pCI) in the presence of heparin. Normal human plasma contains an average of 0.3mg/ml. The normal newborn has a protein C level that is 30 to 40% of the normal adult level. Numerous cases with a genetical protein C deficiency associated with thrombotic disease have been reported, frequently with an extensive family history of thrombosis. Patients with a partial protein C deficiency are subject to severe, recurrent deep venous thrombosis and pulmonary embolism. The plasma protein C level should be determined before beginning anticoagulation therapy. Total protein C deficiency in the newborn leads to purpurea fulminans; the diagnosis may be confirmed by determining the protein C levels in both heterozygous parents. Acquired protein C deficiency may result of treatment with oral anticoagulants and of various liver diseases. Plasma protein C levels may also decrease after intravascular coagulation.
Catalog #P9102-30C
ApplicationsSuitable for use in Immunoelectrophoresis Double Radial Immunodiffusion, ELISA and Immunoprecipitation. Other applications not tested.
Recommended DilutionNote: Plasma samples and all assay components must contain EDTA to stabilize the proteins.
Optimal dilutions to be determined by the researcher.
Storage and StabilityLyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. 
Clone TypePolyclonal
ConcentrationNot determined
FormSupplied as a lyophilized powder. Preservative free. Reconstitute with 1ml sterile ddH2O. Dilute further in PBS, pH 7.2.
ImmunogenHuman Protein C
SpecificityRecognizes human Protein C. Precipitation obtained in gel immunoelectrophoresis and double radial immunodiffusion (Ouchterlony) against fresh plasma and serum shows a reaction of identity with that obtained with the purified protein C. No reaction is obtained with any
other plasma or serum protein component. May also react with complexes of protein C with protein S. Does not crossreact with any other component of human plasma.
Important NoteThis product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.

External Links